# OGA

## Overview
The OGA gene encodes the enzyme O-GlcNAcase, which is pivotal in the regulation of protein function through the removal of O-linked Î²-N-acetylglucosamine (O-GlcNAc) modifications from proteins. This enzyme is essential for maintaining the balance of protein O-GlcNAcylation, a modification critical for numerous cellular processes including signal transduction, transcription, and metabolism. O-GlcNAcase, a multi-domain protein, includes a catalytic domain that belongs to the glycoside hydrolase family 84, a stalk domain aiding in dimerization, and a C-terminal pseudo-histone acetyltransferase domain, which, despite its name, does not exhibit typical HAT activity (Li2017Structural; Li2017Structures). The enzyme's ability to interact with a broad range of substrates underscores its role as a central regulator in cellular function, akin to the role of phosphatases in dephosphorylation processes (King2019Molecular).

## Structure
The human O-GlcNAcase (OGA) protein, encoded by the MGEA5 gene, exhibits a complex molecular structure that is crucial for its function in regulating protein functions through the hydrolysis of O-linked Î²-N-acetyl glucosamine (O-GlcNAc) modifications on proteins. OGA is a multi-domain protein consisting of an N-terminal catalytic domain, a stalk domain, and a C-terminal pseudo-histone acetyltransferase (HAT) domain (Li2017Structural; Li2017Structures). The catalytic domain belongs to the glycoside hydrolase family 84 (GH84) and is characterized by a (Î²/Î±)8-barrel structure, which includes an eight-stranded parallel Î²-sheet core surrounded by eight Î±-helices (Li2017Structures). This domain is responsible for the enzyme's hydrolase activity, crucial for removing O-GlcNAc modifications from substrates.

The stalk domain, primarily composed of six Î±-helices, plays a significant role in the stability and dimerization of the protein. The interaction between the stalk domains of two monomers is essential for forming the functional dimeric state of OGA, which is distinct from its bacterial homologs (Roth2017Structural; Li2017Structures).

The C-terminal domain, despite its sequence homology to HAT enzymes, lacks key residues necessary for acetyl-coenzyme A binding, suggesting a different functional role which remains to be fully elucidated (Li2017Structures; Elbatrawy2020OâGlcNAcase:). This domain's involvement in protein interactions or structural integrity highlights its importance beyond enzymatic activity.

OGA exists in multiple isoforms due to alternative splicing, with notable variants including a long form that contains all domains and a short form lacking the C-terminal HAT-like domain. These isoforms differ in their cellular localization and enzymatic activity, influencing the protein's functional diversity (Kim2007Distinctive; Elbatrawy2020OâGlcNAcase:).

## Function
O-GlcNAcase (OGA) is a critical enzyme in human cells, encoded by the OGA gene, that regulates the post-translational modification of proteins through the removal of O-linked N-acetylglucosamine (O-GlcNAc) from serine or threonine residues. This modification is pivotal for various cellular functions such as signal transduction, transcription, and metabolism. OGA operates by counteracting the activity of O-GlcNAc transferase (OGT), which adds O-GlcNAc groups to proteins. The dynamic balance between OGA and OGT is essential for maintaining cellular homeostasis and is linked to the regulation of numerous cellular processes including cell cycle progression, stress response, and gene transcription (Yang2017Protein; Zhang2014O-GlcNAcase).

OGA is known for its broad substrate specificity, which allows it to act on various proteins across different cellular pathways, similar to the role of protein phosphatases in dephosphorylation. This enzyme's activity is crucial in preventing the accumulation of O-GlcNAc modifications that could potentially disrupt normal cellular functions. Disruptions in O-GlcNAc homeostasis, regulated by OGA, are associated with several diseases, including cancer, diabetes, and neurodegenerative disorders (King2019Molecular; Roth2017Structural).

In terms of molecular structure, OGA contains a catalytic domain that interacts with substrates at a V-shaped active site, crucial for its enzymatic function. The enzyme's interaction with substrates primarily involves the peptide backbone rather than specific amino acid sequences, which explains its ability to recognize and modify a wide array of proteins (King2019Molecular). This broad activity spectrum underscores OGA's role as a central regulator of protein function and signaling pathways in human cells.

## Clinical Significance
Mutations in the OGA gene and alterations in its expression have been linked to a range of clinical conditions and diseases. For instance, a mutation in the OGA gene in the Goto-Kakizaki rat is associated with diabetes, highlighting a potential genetic predisposition to metabolic disorders influenced by OGA dysfunction (Chatham2021Role). Additionally, global OGA haploinsufficiency in mice leads to complex metabolic regulation issues, including resistance to obesity induced by a high-fat diet and alterations in body fat and energy expenditure, suggesting a role in metabolic diseases (Chatham2021Role).

In neurodevelopmental and neurodegenerative disorders, reduced expression of OGA has been observed in mouse embryonic stem cell lines with mutations in OGT, which is associated with intellectual disabilities and developmental delays in humans (Muha2021Loss). Furthermore, deregulation of O-GlcNAcylation, where OGA plays a key role, has been associated with Alzheimer's disease and Parkinson's disease, indicating its significance in the pathogenesis of these conditions (Muha2021Loss).

Elevated levels of O-GlcNAcylation due to OGA mutations also contribute to developmental defects, as seen in mouse models where specific mutations lead to perinatal lethality and organ-specific abnormalities (Muha2021Loss). These findings underscore the critical role of OGA in normal development and its potential involvement in the pathogenesis of various chronic and developmental diseases.

## Interactions
Human O-GlcNAcase (OGA) interacts with O-GlcNAc transferase (OGT) in a complex manner that significantly influences its structural and functional state. When OGA binds with OGT, it undergoes a conformational shift from a domain-swapped homodimer to a monomeric form. This interaction involves the glycoside hydrolase domain of OGA docking onto the TPR11 and TPR12 domains of OGT, with additional interactions involving the intrinsically disordered region (IDR) of OGA with the TPR domain of OGT. This binding disrupts the normal dimerization of OGA, inhibiting its enzymatic activity by occluding catalytic residues and the substrate-binding cleft, thus preventing normal dimerization and function (Lu2023Cryo-EM).

Moreover, OGA's IDR interacts with OGT through residues 377-442, with specific residues 394-407 interacting with the glycosyltransferase domain of OGT, and residues 408-442 mainly contacting the TPR domain of OGT. These interactions are characterized by a series of non-covalent interactions, including hydrogen bonds and extensive non-bonded interactions, which are crucial for the association between OGA and OGT (Lu2023Cryo-EM).

Additionally, OGA forms multiprotein complexes that are essential for understanding its biological functions in various cellular contexts, including cancer. High-throughput studies and proteomics have identified numerous OGA binding partners, indicating that OGA interacts with a diverse array of proteins, which can significantly impact cellular functions and disease progression (Hu2022The).


## References


[1. (Chatham2021Role) John C. Chatham, Jianhua Zhang, and Adam R. Wende. Role of o-linked n-acetylglucosamine protein modification in cellular (patho)physiology. Physiological Reviews, 101(2):427â493, April 2021. URL: http://dx.doi.org/10.1152/physrev.00043.2019, doi:10.1152/physrev.00043.2019. (143 citations) 10.1152/physrev.00043.2019](https://doi.org/10.1152/physrev.00043.2019)

[2. (Li2017Structural) Baobin Li, Hao Li, Chia-Wei Hu, and Jiaoyang Jiang. Structural insights into the substrate binding adaptability and specificity of human o-glcnacase. Nature Communications, September 2017. URL: http://dx.doi.org/10.1038/s41467-017-00865-1, doi:10.1038/s41467-017-00865-1. (48 citations) 10.1038/s41467-017-00865-1](https://doi.org/10.1038/s41467-017-00865-1)

[3. (Muha2021Loss) VillÅ Muha, Florence Authier, Zsombor Szoke-Kovacs, Sara Johnson, Jennifer Gallagher, Alison McNeilly, Rory J. McCrimmon, Lydia Teboul, and Daan M.F. van Aalten. Loss of o-glcnacase catalytic activity leads to defects in mouse embryogenesis. Journal of Biological Chemistry, 296:100439, January 2021. URL: http://dx.doi.org/10.1016/j.jbc.2021.100439, doi:10.1016/j.jbc.2021.100439. (34 citations) 10.1016/j.jbc.2021.100439](https://doi.org/10.1016/j.jbc.2021.100439)

[4. (Roth2017Structural) Christian Roth, Sherry Chan, Wendy A Offen, Glyn R Hemsworth, Lianne I Willems, Dustin T King, Vimal Varghese, Robert Britton, David J Vocadlo, and Gideon J Davies. Structural and functional insight into human o-glcnacase. Nature Chemical Biology, 13(6):610â612, March 2017. URL: http://dx.doi.org/10.1038/nchembio.2358, doi:10.1038/nchembio.2358. (109 citations) 10.1038/nchembio.2358](https://doi.org/10.1038/nchembio.2358)

[5. (Zhang2014O-GlcNAcase) Zhen Zhang, Ee Phie Tan, Nicole J. VandenHull, Kenneth R. Peterson, and Chad Slawson. O-glcnacase expression is sensitive to changes in o-glcnac homeostasis. Frontiers in Endocrinology, December 2014. URL: http://dx.doi.org/10.3389/fendo.2014.00206, doi:10.3389/fendo.2014.00206. (139 citations) 10.3389/fendo.2014.00206](https://doi.org/10.3389/fendo.2014.00206)

[6. (Elbatrawy2020OâGlcNAcase:) Ahmed A. Elbatrawy, Eun Ju Kim, and Ghilsoo Nam. Oâglcnacase: emerging mechanism, substrate recognition and smallâmolecule inhibitors. ChemMedChem, 15(14):1244â1257, June 2020. URL: http://dx.doi.org/10.1002/cmdc.202000077, doi:10.1002/cmdc.202000077. (39 citations) 10.1002/cmdc.202000077](https://doi.org/10.1002/cmdc.202000077)

[7. (King2019Molecular) Dustin T. King, Alexandra Males, Gideon J. Davies, and David J. Vocadlo. Molecular mechanisms regulating o-linked n-acetylglucosamine (o-glcnac)âprocessing enzymes. Current Opinion in Chemical Biology, 53:131â144, December 2019. URL: http://dx.doi.org/10.1016/j.cbpa.2019.09.001, doi:10.1016/j.cbpa.2019.09.001. (48 citations) 10.1016/j.cbpa.2019.09.001](https://doi.org/10.1016/j.cbpa.2019.09.001)

[8. (Hu2022The) Chia-Wei Hu, Jinshan Xie, and Jiaoyang Jiang. The emerging roles of protein interactions with o-glcnac cycling enzymes in cancer. Cancers, 14(20):5135, October 2022. URL: http://dx.doi.org/10.3390/cancers14205135, doi:10.3390/cancers14205135. (8 citations) 10.3390/cancers14205135](https://doi.org/10.3390/cancers14205135)

[9. (Li2017Structures) Baobin Li, Hao Li, Lei Lu, and Jiaoyang Jiang. Structures of human o-glcnacase and its complexes reveal a new substrate recognition mode. Nature Structural &amp; Molecular Biology, 24(4):362â369, March 2017. URL: http://dx.doi.org/10.1038/nsmb.3390, doi:10.1038/nsmb.3390. (93 citations) 10.1038/nsmb.3390](https://doi.org/10.1038/nsmb.3390)

[10. (Kim2007Distinctive) Eun J. Kim, Benjamin Amorelli, Mohannad Abdo, Craig J. Thomas, Dona C. Love, Spencer Knapp, and John A. Hanover. Distinctive inhibition of o-glcnacase isoforms by an Î±-glcnac thiolsulfonate. Journal of the American Chemical Society, 129(48):14854â14855, November 2007. URL: http://dx.doi.org/10.1021/ja076038u, doi:10.1021/ja076038u. (41 citations) 10.1021/ja076038u](https://doi.org/10.1021/ja076038u)

[11. (Yang2017Protein) Xiaoyong Yang and Kevin Qian. Protein o-glcnacylation: emerging mechanisms and functions. Nature Reviews Molecular Cell Biology, 18(7):452â465, May 2017. URL: http://dx.doi.org/10.1038/nrm.2017.22, doi:10.1038/nrm.2017.22. (729 citations) 10.1038/nrm.2017.22](https://doi.org/10.1038/nrm.2017.22)

[12. (Lu2023Cryo-EM) Ping Lu, Yusong Liu, Maozhou He, Ting Cao, Mengquan Yang, Shutao Qi, Hongtao Yu, and Haishan Gao. Cryo-em structure of human o-glcnacylation enzyme pair ogt-oga complex. Nature Communications, October 2023. URL: http://dx.doi.org/10.1038/s41467-023-42427-8, doi:10.1038/s41467-023-42427-8. (4 citations) 10.1038/s41467-023-42427-8](https://doi.org/10.1038/s41467-023-42427-8)